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Abstract: The performance of the novel chitin metal silicate (CMS) co-precipitates as a 
single multifunctional excipient in tablet formulation using direct compression and wet 
granulation methods is evaluated. The neutral, acidic, and basic drugs Spironolactone 
(SPL), ibuprofen (IBU) and metronidazole (MET), respectively, were used as model drugs. 
Commercial Aldactone
®, Fleximex
®  and Dumazole
® tablets containing SPL, IBU and 
MET, respectively, and tablets made using Avicel
®  200, were used in the study for 
comparison purposes. Tablets of acceptable crushing strength (>40 N) were obtained using 
CMS. The friability values for all tablets were well below the maximum 1% USP tolerance 
limit. CMS produced superdisintegrating tablets (disintegration time < 1 min) with the 
three model drugs. Regarding the dissolution rate, the sequence was as follow:   
CMS > Fleximex
® > Avicel
® 200, CMS > Avicel
® 200 > Dumazole
® and Aldactone
® > 
Avicel
® 200 > CMS for IBU, MET and SPL, respectively. Compressional properties of 
formulations were analyzed using density measurements and the compression Kawakita 
equation as assessment parameters. On the basis of DSC results, CMS co precipitates were 
found to be compatible with the tested drugs. Conclusively, the CMS co-precipitates have 
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the potential to be used as filler, binder, and superdisintegrant, all-in-one, in the design of 
tablets by the direct compression as well as wet granulation methods. 
Keywords: chitin metal silicate co-precipitates; direct compression; wet granulation; 
multifunctional single tablet excipient 
 
1. Introduction 
Excipients are known to have a defined function when incorporated in pharmaceutical dosage 
forms. These are added to modulate manufacturing and delivery of drug substances. The better the 
excipient can fulfill these functions, the more ideal that excipient is [1].  
In solid dosage forms, particularly immediate release tablets and capsules, excipients are added to 
facilitate processing because they are used to bulk the product, lubricate the powder, ease the flow and 
facilitate compression of the powder bed [2]. Stability and solubility of the drug substance can be 
improved by including suitable excipients. This improvement enhances the bioavailability
  [3]. 
However, the introduction of an added excipient to the formulation brings with it new challenges 
concerning the drug-excipient interaction [4]. Therefore, manufacturers of solid dosage forms are 
always trying to reduce the number of excipients in their products. In addition, the introduction of new 
high speed tablet machinery requires excipients with good compressibility, compactablity,  flow 
properties and even short dwell times. These requirements for such excipient specifications have led to 
most available ones falling short in fulfilling their role. 
Excipients can be modified by manufacturing process to produce new grades of the present 
excipients, for example the modification of starch to become soluble or spray dried lactose to assist its 
followability [5]. Common excipients are modified by coprocessing with other excipients in order to 
offer excipients with added advantages. For example: Microcrystalline cellulose (MCC) was 
coprocessed with (silicone dioxide) SiO2 to obtain a high compatibility and high intrinsic flow with 
enhanced lubricant activity, yielding a better tablet hardness especially when wet granulation was used
 
[6]. Coprocessing of lactose or calcium carbonate with MCC produced excipient suitable for direct 
compression [7,8]. 
Still there is a need for new excipients, which has led to some research groups suggesting the usage 
of chitosan [9]. Recently, chitosan was evaluated for its function as an excipient due to its ability to act 
as a fast disintegrating agent. Its flowability was improved by coprocessing with SiO2 [10]. Later, this 
co-processed chitosan was found to suffer from chemical activity with many drug substances due to 
the presence of free NH2 and SiO2 groups. This resulted in the development of a novel excipient based 
on chitin coprocessed with silica. Such modification overcomes the chemical reactivity in chitosan 
SiO2 mixture [11]. 
Recently, Rashid et al. [12] prepared and characterized three co precipitates of metal silicates (i.e., 
calcium, magnesium, and aluminum) onto chitin particles, which can be compressed into rapid 
disintegrating compacts. The different metal silicates co-precipitated on the chitin particles provide 
different excipient pH, for example, the pH of chitin-Al silicate, chitin-Mg silicate, and chitin-Ca 
silicate are ranging between 3–6, 9.5–10, and 10–11 respectively. Consequently, it becomes necessary Mar. Drugs 2010, 8 
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to test the suitability of these excipients to be used as a single component mixed with some active drug 
substances and to study their influence on the tablet’s properties and preparation methods. 
In the present work, the use of co-precipitates of chitin Ca, Mg, and Al silicates as a single 
multifunctional excipient in tablet preparation of problematic drugs: ibuprofen (IBU), metronidazole 
(MET) and spironolactone (SPL) is evaluated.  
2. Results and Discussion 
2.1. Preparation and Characterization of Metal Silicate and Their Compacts 
Ca, -Mg, and -Al ions are capable of forming complexes with silicate ions, leading to the formation 
of insoluble metal silicates according to the following equations, respectively: 
CaCl2 + Na2SiO3   CaSiO3 + 2NaCl  (1)
MgCl2 + Na2SiO3   MgSiO3 + 2NaCl  (2)
2AlCl3 + 3Na2SiO3   Al2(SiO3)3 + 6NaCl  (3)
These insoluble metal silicates were deposited on a chitin surface as reported earlier [12]. The pH of 
the media of the co-precipitation of calcium, magnesium, and aluminum silicates on chitin particles 
was measured as 10, 9, and 4, respectively. This highlights the basic nature of calcium and magnesium 
cations and the acidic nature of aluminum cations, which can be utilized in improving the dissolution 
of acidic and basic drugs. In a previous study, the resulted co-precipitate was found to be an 
amorphous powder [12]. 
2.2. Drug Excipient Compatibility  
Differential scanning calorimetry (DSC) was used as a technique to measure the compatibility of 
the drugs with chitin-metal silicate (CMS) by measuring the physical transformation of the drugs when 
they undergo phase transitions due to endothermic or exothermic heat flows. Examples of such 
thermograms are presented in Figures 1 and 2. 
All the CMS(s) showed broad spectrum endothermic peaks at 30–120 ºC (Figure 1). Many authors 
[13] related the presence of such broad spectrum peak in this region to water evaporation of   
polymeric materials. 
Sharp endothermic peaks due to melting at 76, 160 and 210 ºC were recorded for IBU, MET and 
SPL, respectively. Endothermic peaks shown above 250 ºC are due to the decomposition of chitin 
itself. The melting endotherms of the physical mixture of the drugs with CMS were well preserved 
with slight changes in terms of broadening or shifting towards lower temperatures (Figures for MET 
and SPL are not shown). It has been reported that the quantity of material used, especially in   
drug-excipient mixtures, affects the peak shape and enthalpy. Thus, these changes in the melting 
endotherm could be due to the mixing process, which lowers the purity of each component in the 
mixture, and may not necessarily indicate potential chemical incompatibility [14]. However, as the 
physical interaction may affect the crystalline structure, this may be correlated to the observed 
lowering in the melting endotherms. Such results indicate no chemical interaction is detectable. 
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Figure 1. DSC of chitin Ca silicate (blue), chitin Mg silicate (red) and chitin Al silicate 
(black). 
 
Figure 2. Comparison between ibuprofen alone (IBU) and ibuprofen with chitin calcium 
silicate (IBU + CCaS). 
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2.3. Compression Studies Analysis 
The compression behavior of the three model drugs, CMgS, and mixture of CMgS with the drugs 
were analyzed using the Heckel equation (Equation 4).  
Powders of MET and SPL failed to form solid compacts at the pressures applied (2.7–44.2 MPa), 
while IBU was compressed easily over this pressure range. However, it was not possible to obtain 
Heckel plots since these powders form non porous solid that formed a low volume tablet. 
Table 1. Parameters obtained from Heckel plots. 
Formula  Py  A  DA A 0 D 0 D B 
IBU(400 mg) + CMgS(300 mg)  81.97  1.7  0.82  0.4811  0.38  0.44 
MET(500 mg) + CMgS(300 mg)  86.21  1.53  0.78  0.3592  0.30  0.48 
SPL(25 mg) + CMgS(275 mg)  103.10  1.19  0.70  0.2324  0.21  0.49 
Chitin Mg-silicate  153.85  0.72  0.51  0.1641  0.15  0.36 
Heckel plots (not shown) of CMgS, CMgS with IBU, MET, or SPL showed pronounced initial 
curvature followed by a linear portion. This is an indicator of intensive particle rearrangements and 
fragmentation followed by plastic deformation. All tested formulas showed similar Heckel plots, 
which mean that the addition of drugs did not affect the shape of the Heckel plot. Different parameters 
were obtained from Heckel plots and are presented in Table 1. The Py values, which represent the yield 
pressure (i.e., the least pressure at which particle plastic deformation is initiated), decreased from 
153.9 MPa; for the single excipient, i.e., chitin Mg silicate (CMgS), to 82, 86.3, and 103.1 MPa for the 
mixtures of the same excipient with IBU, MET and SPL drugs, respectively (calculated p < 0.05 of the 
yield pressure values between that of the single excipient and that of the excipient with the 
incorporated drugs). This implies that, the onset of plastic deformation of CMgS occurred at lower 
pressure in the presence of drugs [15]. This implies that CMgS can be useful in high-speed tablet 
machines with short dwell time, where faster onset of plastic deformation should be useful in avoiding 
problems of lamination and capping [16]. 
The D0 value, which represents the degree of initial packing in the die as a result of die filling for 
CMgS, increased in the presence of drugs and were in the order: CMgS with IBU > CMgS with  
MET > CMgS with SPL > CMgS. This shows that the CMgS/drug mixtures exhibit higher degree of 
packing in the dies as a result of die filling than CMgS powder alone.  
The value of DB represents the phase of rearrangement of the particles in the early stages of 
compression. The DB value of CMgS powder alone was 0.36 and increased to 0.44, 0.48, 0.49 for 
CMgS with IBU, CMgS with MET, and CMgS with SPL, respectively. This increase indicates that the 
fragmentation of the powder mixture is more pronounced than the CMgS alone. The value of DA, 
which represents the total degree of packing achieved at zero and low pressure (i.e.,  D0 + DB), 
increased for CMgS in the presence of drugs. 
Figure 3 showed Kawakita plots for CMgS alone and CMgS with IBU, MET and SPL, respectively. 
A linear relationship between P/C and P was obtained at all applied compression pressures with a 
correlation coefficient ≥ 0.99. Values of “1/a” and “1/ab” were obtained from the slope and intercept 
of the plots, respectively, and are summarized in Table 2.  
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Table 2. Parameters obtained from Kawakita plots. 
Formula  1/ab 1/a  a  1/b  R² 
IBU + CMgS  0.33  1.16  0.86  0.29  1.0000 
MET + CMgS  0.80  1.24  0.80  0.36  0.9998 
SPL + CMgS  0.49  1.15  0.87  0.43  1.0000 
CMgS 0.82  1.17  0.85 0.69 1.0000 
From the table, the value of “a” parameter, which represents the compressibility (total volume 
reduction) of the powder before compression, for CMgS alone was not significantly different   
(p > 0.05) from the “a” values of CMgS with the drugs. This means that the addition of a drug to the 
excipient did not significantly alter the measured compressibility of the powder.  
The value of “1/b” for CMgS was higher than CMgS with drugs. The lower value of “1/b” of 
CMgS in the presence of drugs is indicative of the reduction in cohesive forces. In other words, the 
drugs increased the total degree of plastic deformation of CMgS during the compression process. 
These results positively correlate with Heckel parameter “Py”. 
Figure 3. Kawakita plots of chitin Mg silicate alone (CMgS) and with ibuprofen (IBU), 
metronidazole (MET), and spironolactone (SPL). 
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2.4. Physical Properties of the Tablets  
The physical properties of all the tablet formulations are presented in Table 3. All tablets passed the 
current USP friability test, showing the % friability value well below the 1% upper level of 
acceptability for pharmaceutical tablets (USP, 2007). The formulated tablets showed thicknesses that 
are comparable to their respective commercial products. Acceptable content uniformity of the 
produced tablets was obtained ranging from 98 ± 2 to 101 ± 2%. Regarding the crushing strength, the 
results are in good agreement with the friability data and are considered to be acceptable values   
(>40 N) [17]. The higher thickness values for tablets made using CMS compared to that of Avicel
® 
200 tablets is due to the high elasticity of these material. Mar. Drugs 2010, 8 
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Table 3. Physical properties of the prepared tablets. 
Formula #  Drug  Tablet content (%)  Tablet thickness (mm)  Tablet friability (%) 
F1  IBU  98 ± 2  0.71 ± 0.04  0.32 ± 0.05 
F2  IBU  101 ± 2  0.73 ± 0.05  0.42 ± 0.05 
F3  IBU  98 ± 03  0.74 ± 0.05  0.31 ± 0.05 
F4  IBU  100 ± 2  0.63 ± 0.04  0.40 ± 0.03 
F5  IBU  99 ± 2  0.74 ± 0.04  0.36 ± 0.05 
F6  IBU  101 ± 2  0.75 ± 0.04  0.33 ± 0.04 
F7  MET  98 ± 2  0.63 ± 0.04  0.29 ± 0.05 
F8  MET  99 ± 2  0.65 ± 0.04  0.38 ± 0.03 
F9  MET  98 ± 2  0.62 ± 0.04  0.35 ± 0.04 
F10  MET  101 ± 2  0.57 ± 0.04  0.36 ± 0.05 
F11  MET  99 ± 2  0.63 ± 0.04  0.42 ± 0.03 
F12  MET  101 ± 2  0.63 ± 0.04  0.39 ± 0.04 
F13  SPL  100 ± 2  0.38 ± 0.04  0.41 ± 0.05 
F14  SPL  98 ± 2  0.39 ± 0.04  0.44 ± 0.05 
F15  SPL  99 ± 2  0.40 ± 0.03  0.39 ± 0.05 
F16  SPL  100 ± 2  0.29 ± 0.05  0.47 ± 0.05 
Flexamex®  IBU  101 ± 2  0.57 ± 0.05  NR* 
Dumozole®  MET  99 ± 2  0.63 ± 0.05  NR 
Aldactone®  SPL  98 ± 2  0.36 ± 0.04  0.56 ± 0.05 
* NR means not required due to the presence of a film coat. 
Figures 4–6 represent the crushing strengths and the disintegration times of the tablets prepared by 
direct compression using CMS in comparison with Avicel
® 200 (one of the most commercially used 
excipient in direct compression) and the respective commercial products. The crushing strengths of all 
tablet formulation were within 100–115 N. No significant difference (p  > 0.05) in the crushing 
strengths was found between the three CMS. It showed superdisintegration properties. The three drug 
formulations disintegrated in less than one minute (p > 0.05). On the other hand, Avicel
® 200 tablets 
disintegrated in 15 min, less than one minute, and 5 min for IBU, MET, and SPL tablets, respectively.  
The CMgS was used as intra-granular as well as extra-granular in the preparation of IBU and MET 
tablet formulations using the wet granulation method. The crushing strength and disintegration time 
results obtained are summarized in Table 4.  
Table 4. Effect of wet granulation on crushing strength and disintegration time of CMgS 
tablets. WIG: wet intragranulation, WEG: wet extragranulation. 
Formula #   Crushing strength (N) Disintegration  time  (min) 
F05 (WIG, IBU)  104 ± 5  <1 min 
F06 (WEG, IBU)  75 ± 5  <1 min 
F11 (WIG, MET)  71 ± 5  <1 min 
F12 (WEG, MET)  43 ± 5  <1 min 
From the above results it can be concluded that intra-granular method resulted in harder tablets than 
extra-granular method, and this could be due to the binding effect of water used in the granulation. Mar. Drugs 2010, 8 
 
 
1706
 
Intra-granulation enhances distribution of the inactive material (CMgS) in closer fashion around the 
active particles, enhancing bond formation between the active and inactive materials, which both form 
a single entity as a result of drying. The superdisintegration property of CMgS was not lost due to wet 
granulation; the tablets disintegrate in less than one minute. Such results enforce the idea that this 
multifunctional excipient can be used in dry and wet granulation with preferential addition as 
intragranulation method.  
Figure 4. Crushing strength and disintegration times of tablets prepared from IBU and 
CCaS, or CMgS, or CAlS, or Avicel 200® excipients. Fleximex
® was used as a model 
commercial drug reference.  
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Figure 5. Crushing strength and disintegration times of tablets prepared from MET and 
CCaS, or CMgS, or CAlS, or Avicel 200® excipients. Dumazol
® was used as a model 
commercial drug reference. 
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Figure 6. Crushing strength and disintegration times of tablets prepared from SPL and 
CCaS, or CMgS, or CAlS, or Avicel 200® excipients. Aldactone
® was used as a model 
commercial drug reference. 
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2.5. Drug Release Studies  
For IBU tablets, Figure 7, the CMgS and CCaS (Formulas F1 and F2, respectively) released 94% of 
the drug in 10 min while 84% of IBU was released from CAlS tablets (Formula F3) within the same 
time period. 100% of the drug was released from CMgS and CCaS tablets in 10 min, while 20 min and 
30 min was required to release the same amount of the drug from CAlS and Fleximex
® tablets, 
respectively. This criterion of dissolution fulfills the USP criteria for immediate release solid dosage 
forms. Avicel
® 200, in contrast, released only 25% of the drug in 30 min. CalS, which is considered to 
be acidic filler, resulted in an acidic pH-microenvironment around the acidic IBU particles. This could 
be the reason behind the slower release profile compared to the basic fillers CcaS- and   
CMgS-containing tablets. In a similar study, [17] used cellulose II powder as a single filler excipient 
with multi functional action. Drug release from the tablets containing cellulose II powder was faster 
than both the commercial product (Advil
®) and Avicel
® pH 102 containing tablets. They related this 
observation to the faster disintegration of cellulose II containing tablets. It seems that the use of a 
single excipient composed of chitin-Mg, Ca silicate mixtures can be used alone to yield an immediate 
release tablet of IBU similar to what has been reported. 
The effect of the type of CMS was not significantly noticed on MET, since MET is highly soluble 
in the dissolution medium used. Complete MET release was within 5 min from all types of CMS. 
These results reveal that all tablet formulations met the USP drug release tolerance criterion. 
For SPL tablets, preliminary data using release studies using the USP conditions (1000 mL of 0.1 N 
HCl containing 0.1% sodium lauryl sulfate, Paddle, 75 rpm) doesn’t indicate any significant difference 
(p > 0.05) between the commercial product and CMS containing tablets. This could be attributed to the 
presence of hydrochloric acid as an acidic medium that could level off the micro-environmental pH 
differences between different metal silicates present in the CMS tablets. Consequently, water was used 
as a dissolution medium in order to get an insight about the differences in the microenvironment pH Mar. Drugs 2010, 8 
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and its effect on drug release. The comparative release profiles of the water insoluble drug, SPL, are 
presented in Figure 8. The release rate decreased in the order: Aldactone
® > CMgS ~ CAlS ~ CCaS > 
Avicel
® 200. All tablet formulations made using CMS showed negligible difference in the dissolution 
profile (p < 0.05). Certainly, CMS type did not affect the dissolution profile of SPL, since it is a 
neutral drug. The CMS containing formulas showed a significant improvement in drug dissolution rate 
compared to Avicel
® 200 containing formula. However, the market formulation of SPL, Aldactone
®, 
showed a faster dissolution rate than CMS made formula, this could be due to the many excipients 
included in Aldactone
® (such as calcium sulfate, corn starch, hypromellose, polyethylene glycol, 
povidone) [18,19]. SPL is water insoluble drug and to have a dissolution profile comparable with the 
leading brand is a real advance in excipient technology, particularly because its formulation is only 
containing the present multifunctional excipient. 
Figure 7. Dissolution profile of IBU formulated with CCaS, CMgS, CalS, and Avicel
® 200 
release profile. Fleximex
® was used as a model commercial drug reference.  
0
20
40
60
80
100
0 5 10 15 20 25 30
Time (min)
%
 
I
b
u
p
r
o
f
e
n
 
r
e
l
e
a
s
e
CCaS
CMgS
CAlS
Fleximex®
Avicel® 200
 
Figure 8. Dissolution profile of SPL formulated with CCaS, CMgS, CalS, and Avicel
® 200 
release profile. Aldactone
® was used as a model commercial drug reference.  
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2.6. Tablets Prepared by Wet Granulation 
As representative examples, CMgS with IBU and MET were selected to study the effect of wet 
granulation on the dissolution rate of tablets. Figures 9 and 10 illustrate that there was no significant 
difference in drug release between the wet granulation (either inter or intra) and direct compression 
using this novel multifunctional tablet excipient as a single tablet component. It is evident from 
Figures 9 and 10 that regardless of the method used for preparing tablets, the compendial dissolution 
of starting material is obtained. This shows that this excipient is suitable in both dry and   
wet granulation. 
Figure 9. Dissolution profile of IBU formulated with CMgS by direct compression (F01), 
inter granulation (F05), and intra granulation (F06).  
 
Figure 10. Dissolution profile of MET formulated with CMgS by direct compression 
(F07), inter granulation (F11), and intra granulation (F12). 
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3. Experimental  
3.1. Materials  
Chitin (200 μm, Mwt of approximately 600 KD, JBICHEM, Shanghai, China), Microcrystalline 
cellulose (Avicel
®  200, FMC BioPolymer, Philadelphia, PA 19103, USA), Sodium silicate   
penta-hydrate (Na2SiO3.5H2O, BDH, Poole, England), Aluminum chloride hexa-hydrate (AlCl3.6H2O, 
MERCK KGaA, Darmstadt, Germany), Magnesium chloride hexa-hydrate (MgCl2.6H2O, SIGMA 
Chemical Co, St. Louis, MO 63178, USA), Calcium chloride di-hydrate (CaCl2.2H2O, ACROS 
Organics, Geel, Belgium), Ibuprofen (Boots Pharmaceuticals, UK), Metronidazole (G.D Seark and 
company, USA), Spironolactone (Micro, Novachem, India), all raw materials were donated by the 
Jordan Pharmaceutical Manufacturing Co. (JPM, Naor, Jordan). Hydrochloric acid solution conc. 37% 
(HCl, Scharlau Chemie S.A, Spain), Potassium di-hydrogen phosphate (KH2PO4, Merck KGaA, 
Germany), Sodium hydroxide pellets (NaOH, ACROS organics, USA). The reference tablets were as 
follows; Fleximex
® 400 mg tablets, Film coated (Alpharma Aps Company, Copenhagen, Denmark) as 
Ibuprofen tablets, Dumazol
® 500 mg tablets, Film coated (Alpharma Aps, Copenhagen, Denmark) as 
Metronidazole tablets, Aldactone
® 25 mg tablets, Film coated (SEARLE Company, High Wycombe, 
England) as Spironolactone tablets. All other reagents used were of analytical grade. 
3.2. Methods 
3.2.1. Preparation of Three Chitin Metal Silicates (CMS): Chitin-Ca, -Mg and -Al Silicate Co 
Precipitates 
All chitin-Ca, -Mg, and –Al silicate co precipitates were prepared according to the method 
described by Rashid et al, 2009 [12]. Briefly, into three separate solutions, each containing 10.0 g of 
sodium silicate dissolved in 400 mL deionized water, 7.5, 10, and 11.5 g of chitin was added. 
Respectively, 6.0 g of AlCl3.6H2O, 9.6 g of MgCl3.6H2O, 6.9 g of CaCl3.2H2O were added 
stoichiometrically and allowed to react with sodium silicate to produce suspended particles of the 
insoluble metal silicate that co precipitated onto chitin. The particles were filtered out using 20–25 m 
filter papers (ALBET 135, Quantitative, Spain) then washed with deionized water. The product was 
dried in the oven at 90 ºC, and finally passed through a mesh of 425 µm size and kept for further 
testing and characterization. 
3.2.2. Characterization of the Compacts 
3.2.2.1. Compatibility Study  
For DSC studies, about 5 ± 0.5 mg of each of the drugs (IBU , MET and SPL), the three CMS 
(CCaS, CMgS and CAlS) and a mixture (1:1 drug to CMS w/w) were weighed into an aluminum 
crucible, which was then pierced and the DSC run was carried out using DSC 823, Mettler Toledo Star 
system, Switzerland. The instrument was initially calibrated with indium. Scanning runs were 
performed under atmospheric conditions. A heating rate of 10 ºC/min was used for all samples. Mar. Drugs 2010, 8 
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3.2.2.2. Characterization of Compacts by Heckel and Kawkita Plots 
Chitin- metal silicate (Al, Mg, Ca), Ibuprofen (IBU) and spironolactone (SPL) were separately 
compressed by direct compression using a universal testing machine (UTM, RKM 50, PR-F System; 
ABS Instruments Pvt., Ltd., Leipzig, Germany). This was achieved without lubrication of the upper 
and lower punches as well as the dye. The punch speed was fixed at 10 mm/min. Different 
compression forces from 2.7–44.2 MPa were applied. Three tablets were prepared to ensure 
reproducibility. The tablets were flat, round with a 12 mm diameter, and 400 mg in weight. The 
compression behavior of the prepared compacts was evaluated according to Heckel and Kawakita 
equations.  
The compression behavior of the samples was evaluated using the Heckel equation (Equation 4) 
A KP
D
  





 1
1
ln          ( 4 )  
where D is the relative density of the compact at pressure P; K is the slope; and A is the intercept of the 
straight line obtained by linear regression from the Heckel plot. 
The relative density, D0, of the powder at the point when the applied pressure equals zero is used to 
describe the initial rearrangement phase of densification as a result of die filling and high value 
indicating very dense packing. The relative densities DA and D0 were calculated from Equations (5) 
and (6), respectively:  
DA =1-e
-A         ( 5 )  
D0=1-e-
A
0         ( 6 )  
where A0 represents the intercept of the line at P=0. The difference between DA and D0 represents the 
extent of particle rearrangement (DB). The relative density DB, describes the phase of arrangement 
during the initial stages of compression. The extent of this depends on the theoretical point of 
densification at which particle deformation begins. The mean yield pressure (Py) was obtained as the 
reciprocal of the slope of the linear section in the curve. Py is inversely related to the ability of the 
material to deform plastically under pressure [20,21]. 
The Kawakita equation (Equation 7) is used to study powder compression via the degree of volume 
reduction, C. The basis for the Kawakita equation for powder compression is that particles subjected to 
a compressive load in a confined space are viewed as a system in equilibrium at all stages of 
compression, so that the product of the pressure term and the volume term is a constant [22].  
Equation (1) above can be rearranged in linear form as: 
ab a
P
C
P 1
   
(7)
Where, C is the degree of volume reduction of powder column under the applied pressure, P. The 
constant a is the minimum porosity of the material before compression while the constant b relates to 
the plasticity of the material. The reciprocal of b defines the pressure required to reduce the powder 
bed by 50%. 
The degree of particle rearrangement can be affected simultaneously by the two Kawakita 
parameters, a and b. The combination of these into a single value, i.e., the product of the Kawakita Mar. Drugs 2010, 8 
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parameters  a  and  b, may hence be used as an indicator of the degree of particle rearrangement   
during compression. 
3.2.3. Tablet Preparation 
3.2.3.1. Preparation of Tablets by Direct Compression Method  
The composition of tablet formulations is presented in Table 5. The amounts per tablet of each of 
the three chitin-metal (Ca, Mg, and Al) silicate powders (particle size of 425 μm) or Avicel
® 200 and 
the drugs: ibuprofen (IBU),  metronidazole (MET)  or spironolactone (SPL) were separately and 
accurately weighed and mixed. The pre-weighed mixture was introducing manually in 12 mm die and 
compressed using a hydraulic press (C-30 Research and Industrial Instruments, London). The 
compression forces were set to produce tablets of nearly similar crushing strength and were within 10 
and 150 kN. For each type of drug, a minimum of 100 tablets were prepared. 
3.2.3.2. Preparation of Tablets by Wet Granulation Using Chitin-Mg Silicate 
For wet intra-granulation; CMgS powder and IBU or MET were sieved and blended in a cube mixer 
for 15 min. The mixture was then transferred to a planetary mixer and sufficient water was added to 
form a coherent wet mass. The wet mass was passed through a 2.50 mm sieve and then dried in a hot 
air oven at 50 ºC for enough time to reach a moisture content of <2%. Moisture content was analyzed 
by an Ultra X moisture analyzer (August Gronert Co., Germany). The dried granules were further 
passed through a 0.80 mm sieve. Suitable weight of the final mixture equivalent to 400 mg and 500 mg 
of IBU and MET, respectively, was manually filled in the die and compressed to similar crushing 
strength using the hydraulic press.  
Table 5. Composition of model ibuprofen, metronidazole and spiranolactone tablet formulations. 
Formula #  Drug*  Process  CMgS*  CCaS*  CALS*  Avicel® 200* 
F 1  400 (IBU)  DC  300          
F 2  400 (IBU)  DC    300     
F 3  400 (IBU)  DC      300   
F 4  400 (IBU)  DC        300 
F 5  400 (IBU)  WIG  300       
F 6  400 (IBU)  WEG  300          
F 7  500 (MET)  DC  300          
F 8  500 (MET)  DC    300     
F 9  500 (MET)  DC      300   
F 10  500 (MET)  DC        300 
F 11  500 (MET)  WIG  200       
F 12  500 (MET)  WEG  200          
F 13  25 (SPL)  DC  275       
F 14  25 (SPL)  DC    275     
F 15  25 (SPL)  DC      275   
F 16  25 (SPL)  DC           27 
DC: direct compression, WIG: wet intragranulation, WEG: wet extragranulation. * Amounts in milligrams. Mar. Drugs 2010, 8 
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For wet extra-granulation; IBU and MET were granulated separately to the end point with distilled 
water, the wet mass was passed over 2.50 mm sieve, then dried in a hot air oven at 50 ºC for enough 
time to reach a moisture content of <2%, then the dried granules were re-sieved using 0.80 mm sieve. 
CMgS powder was mixed using the cube mixer with the dried granules of the active ingredients. 
Suitable weight of the final mixture equivalent to 400 mg and 500 mg of IBU and MET, respectively, 
was manually filled in the die and compressed to similar crushing strength using the hydraulic press. 
The amounts of drugs excipient and process used are shown in Table 5. 
3.2.4. Tablet Characterization 
3.2.4.1. Tablet Thickness 
The thickness of 10 randomly selected tablets was determined using a vernier caliper (For-bro 
Engineers, Mumbai, India). The results are expressed as mean values of 10 determinations.  
3.2.4.2. Drug Content Uniformity 
Ten tablets of each drug formulation were weighed individually, crushed and the drug was extracted 
in water. The solution was filtered through a cellulose acetate membrane (0.45 µm) and the drug 
content was determined by UV spectroscopy ((DU
® 6401, BECKMAN COULTER, USA) after a 
suitable dilution. 
3.2.4.3. Dissolution Test 
The dissolution tests were performed using (Erweka DT6, Germany) dissolution apparatus and the 
test conditions are presented in Table 6. The amount of drug released was analyzed 
spectrophotometrically by measuring the absorbance using UV spectrophotometer (DU
® 640i, 
BECKMAN COULTER, USA) at λ 222 nm, λ 275 and λ 242 nm for IBU, MET and SPL, 
respectively. The amounts released were quantitated by the calibration curve method: the 
concentration of the standard solutions used ranged from 0.004 to 0.025 mg/mL, from 0.004 to   
0.024 mg/mL and from 0.005 to 0.014 mg/mL for IBU, MET and SPL, respectively.  
Table 6. Dissolution conditions used for IBU, MET and SPL tablets. 
Ingredient IBU  tablet    SPL tablet  MET Tablet 
USP Apparatus  II  II  II 
Dissolution medium (900 mL)  phosphate buffer pH7.2  Water  0.1 N HCl 
Agitation rate (rpm)  50  75  100 
Temperature (
oC) 37  37  37 
3.3. Statistical Analysis 
Statistical analysis was carried out to compare the effect between different groups or parameters 
using the Analysis of Variance (ANOVA) on a computer software GraphPad Prism ® 4 (GraphPad 
Software Inc. San Diego, USA). Tukey-Kramer multiple comparison tests was used to compare the Mar. Drugs 2010, 8 
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individual differences between the starches. At 95% confidence interval, p values less than or equal to 
0.05 were considered significant. 
4. Conclusions 
The novel CMS co-precipitates could be used as a single filler tablet excipient with multifunctional 
action. The shortcoming excipients such as high moisture and loss of compressibility by MCC upon 
wet granulation were overcome by such a filler. They were successfully used to prepare tablets by 
direct compression, which is the process of choice for tablet manufacturing. Tablets produced using 
these fillers showed superiority regarding disintegration and dissolution profiles when compared with 
commercial products and with those prepared using Avicel
® 200. Tablets produced using these fillers 
also showed good crushing strength and met the USP friability tolerance limit. These fillers showed 
compatibility with acidic drug (ibuprofen), basic drug (metronidazole) as well as neutral drug 
(spironolactone). The compression behavior of the produced tablets represents B-type material, i.e., 
initial phase of fragmentation followed by plastic deformation. The onset of plastic deformation of 
CMgS (as a representative example of CMS) increased in the presence of drugs. This could be useful 
in avoiding problems of capping and lamination in high speed tabletting machines.  
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